Regulatory requirements for conducting Clinical Trials in India
[7] 2.1.2 Documents required[8] * Clinical trial application form * Treasury Challan * Source of bulk drugs * Information in chemicals and pharmaceutical drugs * Pharmacology data of Animals * Toxicology data of animals * Clinical pharmacology information * Regulatory conditions in other countries *...
Gespeichert in:
Veröffentlicht in: | Research journal of pharmacy and technology 2020-03, Vol.13 (3), p.1517-1522 |
---|---|
Hauptverfasser: | , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | [7] 2.1.2 Documents required[8] * Clinical trial application form * Treasury Challan * Source of bulk drugs * Information in chemicals and pharmaceutical drugs * Pharmacology data of Animals * Toxicology data of animals * Clinical pharmacology information * Regulatory conditions in other countries * Information given/ prescribed * Protocol for quality control * Protocol for clinical study * Investigator's Brochure * Case Report Form * Patient data sheet and informed consent form * Investigator list in India and site address 2.1.3 Clinical Trial agreements: According to new rules, The Drug Controller, India is referred as Central Licensing Authority (CLA). According to GSR 227(E), it is mandatory to register BA/BE studies of investigational new drugs under CTRI before enrolling patients for clinical trials. 4.4 Archival of records and retention samples: According to GSR 227(E), it is mandatory to maintain the data and records for 5 years once trial completes or BA/BE study or at least two years after the expiration date of the batch of the new drug product, whichever is later. |
---|---|
ISSN: | 0974-3618 0974-360X 0974-306X |
DOI: | 10.5958/0974-360X.2020.00276.0 |